Original Article Yonsei Med J 2016 Jul574831839 httpdxdoiorg103349ymj2016574831 pISSN 05135796 eISSN 19762437 Fibroblast Growth Factor Receptor 1 Overexpression Is Associated Poor Survival Patients Resected Muscle Invasive Urothelial Carcinoma Seungtaek Lim12 Myoung Ju Koh3 Hyeon Joo Jeong4 Nam Hoon Cho24 Young Deuk Choi256 Do Yeun Cho7 Hoi Young Lee8 Sun Young Rha26910 1Department Internal Medicine Wonju Severance Christian Hospital Wonju 2Department Medicine Graduate School Yonsei University College Medicine Seoul 3Department Pathology Daedong Hospital Busan 4Department Pathology Yonsei University College Medicine Seoul 5Department Urology Yonsei University College Medicine Seoul 6Yonsei Cancer Center Yonsei University Health System Seoul 7Department Hematology Oncology Konyang University College Medicine Daejeon 8Department Pharmacology Myunggok Medical Research Institute College Medicine Konyang University Daejeon 9Division Medical Oncology Department Internal Medicine Yonsei University College Medicine Seoul 10SongDang Institute Cancer Research Yonsei University College Medicine Seoul Korea Purpose To examine usefulness receptor tyrosine kinase expressions prognostic markers therapeutic tar gets muscle invasive urothelial cancer UC patients Materials Methods We retrospectively analyzed data 98 patients muscle invasive UC underwent radical cys tectomy 2005 2010 Yonsei Cancer Center Using formalin fixed paraffin embedded tissues primary tumors im munohistochemical staining human epidermal growth factor receptor 2 HER2 fibroblast growth factor receptor 1 FGFR1 fibroblast growth factor receptor 3 FGFR3 Results There 41 418 44 449 14 142 patients overexpressed HER2 FGFR1 FGFR3 respec tively In univariate analysis significantly shorter median time recurrence TTR 129 months vs 490 months p0008 overall survival OS 223 months vs 527 months p0006 patients FGFR1 overexpression By contrast difference TTR OS according HER2 FGFR3 expression status FGFR1 remained significant prognostic factor OS hazard ratio 223 95 confidence interval 127390 p0006 multivariate analysis Conclusion Our result showed FGFR1 expression FGFR3 adverse prognostic factor muscle invasive UC pa tients radical cystectomy FGFR1 feasible prognosis prediction potential therapeutic target thorough validation muscle invasive UC Key Words Urinary bladder neoplasms receptor tyrosine kinases prognosis cystectomy Received June 9 2015 Revised October 22 2015 Accepted October 23 2015 Corresponding author Dr Sun Young Rha Division Medical Oncology De partment Internal Medicine Yonsei University College Medicine 501 Yon seiro Seodaemungu Seoul 03722 Korea Tel 82222288050 Fax 8223625592 Email rha7655yuhsac The authors financial conflicts Copyright Yonsei University College Medicine 2016 This Open Access article distributed terms Creative Com mons Attribution NonCommercial License httpcreativecommonsorglicenses bync30 permits unrestricted noncommercial use distribution repro duction medium provided original work properly cited INTRODUCTION Urothelial carcinoma UC fourth common malig nancy men ninth common women ac counting estimated new cases 330400 estimated death 123100 patients worldwide 20121 There distinct subtypes UC superficial disease muscle inva sive disease23 Almost 80 patients UC initially di agnosed superficial disease potentially curable transurethral resection Nevertheless majority wwweymjorg 831 experience recurrences 25 eventually develop muscle invasive disease Although standard treat ment muscle invasive disease radical cystectomy ma jority treatment failure systemic relapse distant metas tases4 Since gemcitabine plus cisplatin demonstrated equivalent efficacy superior tolerability compared methotrexate vinblastine doxorubicin cisplatin randomized phase III trial standard treatment advanced metastatic UC5 However standard therapeutic op tion failure cisplatinbased line chemotherapy rendered overall survival OS patients ad vanced UC 2 years Thus clearly unmet need identify molecular markers develop effective therapeutic strategy UC Human epidermal growth factor2 receptors HER2 play crucial role signal transduction pathways cell pro liferation survival angiogenesis metastasis Since trastu zumab recombinant humanized monoclonal antibody tar geted extracellular domain HER2 dramatically changed treatment HER2 amplified breast cancer gastric cancer68 emerging apply thera peutic strategy malignancies Although HER2 ampli fication overexpression UCs exists higher variability ranging 23 80 overexpression 0 32 amplification910 In addition role prognostic marker muscle invasive UC remains troversial1114 Fibroblast growth factor receptors FGFRs play key role regulation proliferation differentiation apopto sis15 Recently clear exists FGF signal ing alteration substantial proportion bladder tumors16 Mutation FGFR3 common genetic alteration superficial UC results constitutive activation recep tor17 strongly associated low tumor grade stage18 While increased expression FGFR3 majority 85 FGFR3mutant superficial tumors achieved overexpression wildtype ceptor18 Muscle invasive bladder tumors overexpress wild type FGFR3 protein well18 These results suggest potential role mutant FGFR3 predominantly superficial UC overexpression wildtype FGFR3 vasive UC Preclinical studies small molecule inhibitor FGFR showed possibility FGFR3 useful therapeutic target UC19 Although relatively little known role FGFRs UC FGFR1 expression known increased majority bladder cancer cell lines regardless tumor stage grade20 increased FGFR1 expression induces increased proliferation cell survival20 However data prognostic role FGFR1 FGFR3 overexpression pa tients muscle invasive UC radical cystectomy Hence aim study examine usefulness HER2 FGFR1 FGFR3 expression prognostic markers FGFR1 Prognostic Factor Muscle Invasive Urothelial Carcinoma therapeutic targets muscle invasive UC patients In ad dition investigated correlations recep tor tyrosine kinases RTKs clinicopathological factors MATERIALS AND METHODS Patients We retrospectively analyzed data 98 patients derwent radical cystectomy muscle invasive UC uri nary bladder 2005 2010 single institute Yonsei Cancer Center We included patients archival tissue samples cystectomy specimen available tu mor histology confirmed UC Patients ex cluded receive neoadjuvant chemotherapy underwent radical cystectomy All patients underwent radical cystectomy bilateral pelvic lymphadenectomy Surgical procedures consisted enbloc radical cystectomy paraaortic lymph node dissection PLND urinary diver sion PLND included internal external iliac obtu rator lymph nodes Tumors restaged according American Joint Commmitee CancerInternational Union Cancer staging 7th edition21 World Health Or ganization reference center tumor grading This study received approval Institutional Review Board conducted accordance Helsinki Declara tion 1975 Immunohistochemical analysis For immunohistochemistry IHC analysis formalinfixed paraffinembedded tissue containing representatives tumor prepared sectioned slides 5um thickness Slides stained monoclonal antibod ies FGFR1 Rabbit AntiHuman FGFR1 polyclonal antibody SPRING Pleasanton CA USA FGFR3 FGFR3 B9 Santa Cruz Dallas TX USA HER2 polyclonal rabbit antihu man cerbB2 oncoprotein DAKO Glostrup Denmark standard IHC previously described18 The level HER2 protein expression assessed intensity percentage staining scored scale 0 39 The evaluation performed invasive com ponent tumor A score 1 defined barely percep tible membrane staining 10 cells score 2 defined weaktomoderate complete membrane stain ing present 10 tumor cells score 3 defined strong complete membrane staining 30 tumor cells A cytoplasmic staining consid ered nonspecific Tumors presenting 2 3 HER2 expres sion considered HER2 overexpression A semiquantitiative scoring adopted 0 tu mor cells negative 1 faint detectable positivity cells 2 weak extensive positivity 3 strong positivity18 832 httpdxdoiorg103349ymj2016574831 Seungtaek Lim et al As established method assessment FGFR1 FGFR3 positivity defined FGFR1 FGFR3 positive cytoplasmic immunereactivity regard staining intensity Fig 1 Immunostaining sessed independent pathologists blinded clinical outcomes regression hazard model p values 005 signifi level All analyses performed SPSS program version 180 SPSS Inc Chicago IL USA RESULTS Statistical analysis OS calculated date cystectomy death cause Time recurrence TTR defined duration cystectomy date documented recurrence Patients alive cut day censored date contact The association clinicopathological parameters evaluated Students ttest numerical variables Pearsons chisquare test categorized variables Kar planMeier curves plotted TTR OS dif ference survival time analyzed logrank test Multi variate survival analysis performed Coxs proportional Patient characteristics The baseline characteristics patients described Ta ble 1 The median age 695 years range 4188 years 82 male 16 female patients Sixty patients 653 muscle invasive disease initial manifestation 34 patients 347 initially diagnosed noninvasive disease treated transurethral resection tumor times ultimately developed muscle invasive disease Regarding pathologic stage cystectomy 23 patients 235 diagnosed tumor confined muscularis pro pria layer T2 tumor invasion T3 T4 observed 75 patients 765 Node involvement A C B D Fig 1 Immunohistochemistry staining 200 urothelial carcinoma showing different grades FGFR1 expression A Negative B Moderate signaling 30 cells C Weak signaling 70 cells D Moderate signaling 70 cells FGFR1 fibroblast growth factor receptor 1 httpdxdoiorg103349ymj2016574831 833 36 patients 367 Overall 58 patients 592 diag nosed stage II III disease 40 patients 408 stage IV disease All tumors assessed high grade tu mor After cystectomy adjuvant chemotherapy given 47 patients 480 There 41 418 44 449 14 142 patients overexpressed HER2 FGFR1 FGFR3 respec tively Fig 2 Table 1 While 28 patients 286 70 patients 714 receptor expression receptors There 19 patients overexpression HER2 FGFR1 5 patients HER2 FGFR3 8 patients FGFR1 FGFR3 Overex pression receptors patients Survival analysis according receptor status With median followup duration 343 months range 1117 months 54 551 recurrences 67 677 deaths Median TTR median OS population 182 months 95 confidence interval CI 128235 373 months 95 CI 217529 respectively We performed univariate analysis TTR OS according receptor status clinical parameters Table 2 Sig nificantly shorter median TTR seen female patients compared male 75 months vs 197 months p0029 moglobin Hb 120 gdL compared Hb 120 gdL 153 months vs 309 months p0021 lymph node positive LN disease compared LNdisease 151 months vs 608 months p0002 lymphovascular invasion compared LVI 135 months vs 384 months p 0002 noninvasive disease initial manifestation compared initial invasive disease 151 months vs 233 months p 0027 Regarding receptor status patients FGFR1 overex pression worse TTR FGFR1 expression 129 months vs 490 months p0008 Fig 3A By contrast difference TTR according HER2 FGFR3 All negative 28 HER2 20 16 2 FGFR1 20 3 5 FGFR3 4 Fig 2 Distribution patients according HER2 FGFR expression status HER2 human epidermal growth factor receptor 2 FGFR fibroblast growth factor receptor FGFR1 Prognostic Factor Muscle Invasive Urothelial Carcinoma receptor status age previous adjuvant chemotherapy Similar results univariate analysis OS fe male patients compared male 112 months vs 405 months p0021 noninvasive disease initial manifestation com pared invasive disease 191 months vs 487 months p 0026 Hb 120 gdL compared 12 gdL 265 months vs 489 months p0029 dissected lymph node number 12 com pared 12 193 months vs 527 months p0005 FGFR1 overexpression 223 months vs 527 months p0006 showed significantly worse survival Fig 3B In multivariate analysis Table 3 FGFR1 noninvasive disease initial manifestation remained significant prog nostic factors TTR hazard ratio 204 95 CI 127 390 p0018 210 95 CI 128417 p0008 respec tively Also significant prognostic factor OS hazard ratio 223 95 CI 127390 p0006 180 95 CI 128417 p0038 respectively We examined interactions receptor status survival In patients FGFR1 expres Table 1 Baseline Characteristics Patients Variables n98 Age yrs Median range Sex Male Female Initial manifestation Noninvasive Invasive T stage pT2 pT3 pT4 Node Negative Positive Grade Low High HER2 IHC Negative 01 Positive 23 FGFR1 Negative Positive FGFR3 Negative Positive Adjuvant chemotherapy No Yes 695 4188 82 16 34 64 23 75 62 36 0 98 57 41 54 44 84 14 51 47 837 163 347 653 235 765 633 367 0 100 582 418 551 449 857 143 520 480 HER2 human epidermal growth factor receptor 2 FGFR fibroblast growth factor receptor IHC immunohistochemistry 834 httpdxdoiorg103349ymj2016574831 Seungtaek Lim et al sion HER2 overexpression tendency shorter TTR 167 months vs reached p0085 OS 427 months vs 763 months p0172 Interestingly patients FGFR1 ex pression HER2 overexpression showed longer TTR 153 months vs 129 months p0208 OS 286 months vs 202 months p0142 statistical significance Clinicopathologic characteristics FGFR1 3 HER2 receptor status Table 4 shows significant difference frequency FGFR1 expression gender FGFR1 overexpression Table 2 Univariate Analysis TTR OS 75 12 16 female patients 39 32 50 male patients p0008 Also FGFR1 overexpres sion frequently node positive patients node negative patients 611 vs 355 p0014 Conse quently frequently stage IV stage II III patients 579 vs 367 p0040 Otherwise significant association variables according recep tor status Variables Overall Age 70 70 Sex Male Female Initial manifestation Noninvasive Invasive Hb 120 120 pT stage T2 T34 pN stage Node negative Node positive LVI No Yes LN number dissected 12 12 HER2 FGFR1 FGFR3 Adjuvant chemotherapy Yes No n 98 54 44 82 16 34 64 59 39 23 75 62 36 63 35 43 55 57 41 54 44 84 14 47 51 Median TTR 95 CI 182 128235 p value 0332 Median OS 95 CI 373 217529 p value 0187 167 106227 214 45383 197 133261 75 00167 151 62240 233 34433 153 55252 309 NA Not reached 161 128235 680 NA 151 106195 384 NA 135 39231 114 20209 204 34374 309 44575 167 40246 490 001025 129 26232 197 125270 153 58249 177 122232 204 46361 0029 0027 0021 0062 0002 0002 0153 0388 0008 0532 0751 394 289498 274 00591 405 216594 112 91133 191 22360 487 305669 265 158371 489 219759 495 268721 295 128463 489 233745 266 209323 495 305684 248 129366 193 73313 527 316738 373 120626 373 185562 527 308747 223 145300 373 192554 248 00502 373 232514 426 130723 0021 0026 0029 0138 0231 0006 0005 0828 0006 0302 0711 TTR time recurrence OS overall survival CI confidence interval Hb hemoglobin LVI lymphovascular invasion LN lymph nodes HER2 human epidermal growth factor receptor 2 FGFR fibroblast growth factor receptor httpdxdoiorg103349ymj2016574831 835 FGFR1 Prognostic Factor Muscle Invasive Urothelial Carcinoma DISCUSSION We investigated prognostic role different RTKs survival patients underwent radical cystectomy muscle invasive UC FGFR1 strong prognostic factor HER2 FGFR3 prognostic impact Although association activating mu tations overexpression FGFR3 lower risk pro gression better survival superficial UC known16 demonstrated prognostic impor tance FGFR1 muscle invasive UC Recently lot focused FGFR path way therapeutic target UC earlier preclinical studies19 development new drugs targeting FGFR pathway Several clinical trials investigate efficacy FGFR inhibitors UC single drug NCT00790426 NCT01732107 combination cytotoxic agents NCT01496534 underway Currently known FGFRs prognostic impact muscle invasive UC Our present study demonstrated overexpression FGFR1 FGFR3 HER2 worse prognostic factor muscle vasive UC prognostic impact FGFR1 sustained adjustment prognostic factors patholog ic stage lymphovascular invasion number dissected lymph nodes Hb level cystectomy One important issues addressed identify target population benefit FGFR target ing drugs Urothelial cancer cell lines overexpression FGFR1 3 respond FGFR inhibitors efficiently cell lines mutation receptors19 To date fluores cent situ hybridization FISH silver situ hybridization generally detection methods FGFR plification gastric cancer breast cancer nonsmall cell lung cancer2224 In present study IHC available inexpensive tools The previous research showed low proportion tumors showing FGFR1 amplification UC explain high fre quency increased expression This discrepancy suggests g n v v r u s e v t l u m u C 10 08 06 04 02 00 FGFR1 No Yes Nocensored Yescensored g n v v r u s e v t l u m u C 10 08 06 04 02 00 FGFR1 No Yes Nocensored Yescensored 0 20 40 60 80 100 120 0 20 40 60 80 100 120 A Fig 3 Survival curves according FGFR1 expression level A Progression free survival B Overall survival FGFR1 fibroblast growth factor receptor 1 Time recurrence months Overall survival months B Table 3 Multivariate Analysis TTR OS Variables FGFR1 vs Female vs male Noninv vs Inv Hb 120 gdL vs 120 gdL pT34 vs pT2 pN vs pN LVI vs LVI Dissected nodes 12 vs 12 TTR time recurrence OS overall survival HR hazard ratio FGFR1 fibroblast growth factor receptor 1 Inv invasive disease initial manifestation Noninv noninvasive disease initial manifestation LVI lymphovascular invasion HR recurrence 204 160 210 161 154 172 139 071 HR death 223 159 180 132 126 084 167 051 p value 0006 0153 0038 0312 0470 0541 0064 0283 p value 0018 0182 0008 0112 0243 0072 0321 0214 836 httpdxdoiorg103349ymj2016574831 Seungtaek Lim et al FGFR1 overexpression result posttranscrip tional regulation altered splicing increased tran script stability dependent gene amplifica tion25 Thus hypothesized IHC detects final protein product suitable method detection FGFR1 overexpression UC Since showed prognostic role FGFR1 overexpression assessed IHC IHC considered relevant technique detect FGFR1 overexpres sion muscle invasive UC However research es true incidence FGFR1 amplification assessed FISH concordance rate IHC FISH warranted identify proper biomarker Also needs validated clinical trials targeting UC patients It observe significant difference frequency FGFR1 overexpression tumors according gender female 75 vs male 39 In addition female pa tients significantly worse TTR OS male patients The fact lost prognostic impact adjustment variables including FGFR1 suggests worse sur vival outcome female patients higher pro portion FGFR1 overexpression Although finding validated large different cohort help iden tify subset patient population likely FGFR1 overexpression benefit therapeutic approach targeted molecular aberration female predominance epidermal growth factor receptor mutation nonsmall cell lung cancer HER2 overexpression observed 41 98 patients 418 range reported previous works The high variability HER2 overexpression incidence prognostic role explained small numbers patients study heterogeneity laboratory tests To overcome limitations assessment HER2 status needs standardized terms antibodies terpretation results In study HER2 overexpression difference survival patients muscle invasive UC radical cystectomy Interestingly result suggested patients HER2 overexpression tend ed better worse survival outcome FGFR1 receptor expression respectively Although surviv al difference statistically significant discrepancies prognostic value HER2 overexpression UC ported previous articles heterogeneity FGFR1 status checked previous works If case UC patients stratified different categories according HER2 FGFR receptor status How Table 4 Patient Characteristics According Receptor Tyrosine Kinase Variables Age yrs FGFR1 n44 n54 p value 0942 FGFR3 HER2 n14 n84 p value n41 n57 Median range 69 4488 71 4187 72 4487 69 4188 Sex Male Female Initial manifestation Noninvasive Invasive T stage T2 T34 Node Negative Positive Overall stage IIIII IV Metastatic lesion Lung Bone Liver Lymph node Brain Carcinomatosis 32 390 12 750 14 412 30 469 10 435 34 453 22 355 22 611 22 367 22 579 6 500 11 733 5 625 21 656 1 1000 1 1000 50 610 4 250 20 588 34 531 13 565 41 547 40 645 14 389 38 633 16 421 6 500 4 267 3 375 11 344 0 00 0 00 0008 0589 0876 0014 0040 11 134 3 188 7 206 7 109 6 261 8 107 10 161 4 111 7 117 7 184 3 250 2 133 2 250 5 156 0 00 0 00 71 866 13 812 27 794 57 891 17 739 67 893 52 839 32 889 53 883 31 816 9 750 13 867 6 750 27 844 1 1000 1 1000 0201 0577 0231 0064 0494 0352 70 4180 69 4288 36 439 5 312 12 353 29 453 12 522 29 387 22 355 19 528 26 433 15 395 4 333 9 600 6 750 15 469 0 00 1 1000 46 561 11 688 22 647 35 547 11 478 46 613 40 645 17 472 34 567 23 605 8 667 6 400 2 250 17 531 1 1000 0 00 p value 0620 0348 0339 0251 0094 0706 FGFR fibroblast growth factor receptor HER2 human epidermal growth factor receptor 2 httpdxdoiorg103349ymj2016574831 837 cautious accept hypothesis validated subsequent trials We hypothesized survival differences muscle invasive tumors initial presentation initial superficial tumors muscle invasion developed later Notably significant difference TTR OS seen groups This finding result distinct pathophysiology molecular level groups simply derived treatment related effect Although results suggest initial manifestation considered important prognostic factor pa tients underwent radical cystectomy muscle invasive UC cautious defined noninvasive disease based pathologic finding transurethral resec tion bladder procedure inherent limitation true pathologic staging Further analysis treatment course explain disparity outcome perform analysis substantial proportion pa tients diagnosed treated superficial disease fore transferred study hospital diag nosed long time cystectomy obtain medical record This study limitations largely retro spective nature First study conducted single cen ter small number patients Thus hard general ize results entire patient cohort Second study based retrospective chart review significant selection bias Third treatment administered largely based guidelines differences treatment protocols follow strategies interval followup CT scan performed In conclusion showed overexpression FGFR1 FGFR3 assessed IHC strongly associated disease recurrence worse OS muscle invasive UC pa tients received radical cystectomy Since high proportion invasive tumors commer cially available drugs targeted pathway considered important therapeutic target future treat ment strategy ACKNOWLEDGEMENTS This research supported grant Korea Health Technology RD Project Korea Health Industry Development Institute KHIDI funded Ministry Health Welfare Republic Korea HI13C2096 REFERENCES 1 Torre LA Bray F Siegel RL Ferlay J LortetTieulent J Jemal A Global cancer statistics 2012 CA Cancer J Clin 20156587108 2 Knowles MA Molecular subtypes bladder cancer Jekyll Hyde chalk cheese Carcinogenesis 20062736173 FGFR1 Prognostic Factor Muscle Invasive Urothelial Carcinoma Nat Rev Cancer 2005571325 4 Stein JP Lieskovsky G Cote R Groshen S Feng AC Boyd S et al Radical cystectomy treatment invasive bladder cancer longterm results 1054 patients J Clin Oncol 20011966675 5 von der Maase H Hansen SW Roberts JT Dogliotti L Oliver T Moore MJ et al Gemcitabine cisplatin versus methotrexate vinblastine doxorubicin cisplatin advanced metastatic bladder cancer results large randomized multinational multicenter phase III study J Clin Oncol 200018306877 6 Slamon DJ LeylandJones B Shak S Fuchs H Paton V Baja monde A et al Use chemotherapy plus monoclonal antibody HER2 metastatic breast cancer overexpresses HER2 N Engl J Med 200134478392 7 Romond EH Perez EA Bryant J Suman VJ Geyer CE Jr Davidson NE et al Trastuzumab plus adjuvant chemotherapy operable HER2positive breast cancer N Engl J Med 2005353167384 8 Bang YJ Van Cutsem E Feyereislova A Chung HC Shen L Sawa ki A et al Trastuzumab combination chemotherapy versus chemotherapy treatment HER2positive advanced gastric gastrooesophageal junction cancer ToGA phase 3 openlabel randomised controlled trial Lancet 201037668797 9 Laé M Couturier J Oudard S Radvanyi F Beuzeboc P Vieillefond A Assessing HER2 gene amplification potential target therapy invasive urothelial bladder cancer standardized methodology results 1005 patients Ann Oncol 2010218159 10 Marín AP Arranz EE Sánchez AR Auñón PZ Barón MG Role antiHer2 therapy bladder carcinoma J Cancer Res Clin Oncol 2010136191520 11 Mellon JK Lunec J Wright C Horne CH Kelly P Neal DE C erbB2 bladder cancer molecular biology correlation epi dermal growth factor receptors prognostic value J Urol 1996 1553216 12 Lönn U Lönn S Friberg S Nilsson B Silfverswärd C Stenkvist B Prognostic value amplification cerbB2 bladder carcino ma Clin Cancer Res 19951118994 13 Vollmer RT Humphrey PA Swanson PE Wick MR Hudson ML Invasion bladder transitional cell carcinoma relation histologic grade expression p53 MIB1 cerb B2 epi dermal growth factor receptor bcl2 Cancer 19988271523 14 Kolla SB Seth A Singh MK Gupta NP Hemal AK Dogra PN et al Prognostic significance Her2neu overexpression patients muscle invasive urinary bladder cancer treated radical cystectomy Int Urol Nephrol 2008403217 15 LHôte CG Knowles MA Cell responses FGFR3 signalling growth differentiation apoptosis Exp Cell Res 2005304417 31 16 di Martino E Tomlinson DC Knowles MA A decade FGF recep tor research bladder cancer past present future challeng es Adv Urol 20122012429213 17 Ornitz DM Itoh N Fibroblast growth factors Genome Biol 20012 REVIEWS3005 18 Tomlinson DC Baldo O Harnden P Knowles MA FGFR3 protein expression relationship mutation status prognostic variables bladder cancer J Pathol 2007213918 19 Lamont FR Tomlinson DC Cooper PA Shnyder SD Chester JD Knowles MA Small molecule FGF receptor inhibitors block FG FRdependent urothelial carcinoma growth vitro vivo Br J Cancer 20111047582 20 Tomlinson DC Lamont FR Shnyder SD Knowles MA Fibroblast growth factor receptor 1 promotes proliferation survival ac tivation mitogenactivated protein kinase pathway blad der cancer Cancer Res 200969461320 3 Wu XR Urothelial tumorigenesis tale divergent pathways 21 Edge S Byrd DR Compton CC Fritz AG Greene FL Trotti A 838 httpdxdoiorg103349ymj2016574831 Seungtaek Lim et al AJCC cancer staging manual 7th ed New York Springer 2010 22 Kim HR Kim DJ Kang DR Lee JG Lim SM Lee CY et al Fibro blast growth factor receptor 1 gene amplification associated poor survival cigarette smoking dosage patients resected squamous cell lung cancer J Clin Oncol 2013317317 23 Jung EJ Jung EJ Min SY Kim MA Kim WH Fibroblast growth fac tor receptor 2 gene amplification status clinicopathologic significance gastric carcinoma Hum Pathol 201243155966 24 Jang M Kim E Choi Y Lee H Kim Y Kim J et al FGFR1 ampli fied progression situ invasive breast carcinoma Breast Cancer Res 201214R115 25 Tomlinson DC Knowles MA Altered splicing FGFR1 associ ated high tumor grade stage leads increased sen sitivity FGF1 bladder cancer Am J Pathol 2010177237986 httpdxdoiorg103349ymj2016574831 839